Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients.
The mutation of Y93H may contribute to treatment failure while L31A may increase the susceptibility to DAAs treatment.
Authors
- Gita Aprilicia
- Juferdy Kurniawan (ORCID: https://orcid.org/0000-0003-2878-169X)
- Anugrah Dwi Handayu
- Darlene Raudhatul Bahri
- Irsan Hasan (ORCID: https://orcid.org/0000-0001-6702-2659)
Institutions
- University of Indonesia (ID)
- Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo (ID)
Publication Details
- Journal
- PubMed
- Published
- 2024-10-01
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00